Key Highlights

  • Total Revenue was USD 83.7 million, up from USD 73.5 million, with net product sales of USD 79.4 million.
  • Income from operations rose to USD 35.4 million from USD 29.7 million, and Net Income was USD 31.7 million.
  • Diluted EPS was USD 0.23, unchanged, as income tax expense rose to USD 7.0 million from USD 0.4 million.
  • Nine-month revenue was USD 244.6 million, and nine-month net income rose to USD 103.5 million.

Revenue and Profit Rise

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported third-quarter 2026 total revenue of USD 83,699,000 compared with USD 73,468,000, an increase of about 14%. Net product sales were USD 79.4 million versus USD 70.6 million, and license, collaboration and Royalty revenue was USD 4.3 million versus USD 2.8 million.

Income from operations was USD 35.4 million versus USD 29.7 million. Net income was USD 31.7 million, or USD 0.24 basic and USD 0.23 diluted per share, versus USD 31.6 million, or USD 0.24 and USD 0.23.

Costs and Taxes

Cost of revenue was USD 8.3 million, and selling, general and administrative expense fell to USD 24.7 million from USD 26.2 million. Research and Development expense doubled to USD 16.6 million from USD 8.4 million. Other income, net was USD 1.3 million versus other expense of USD 0.9 million. Interest income was USD 4.2 million.

Income tax expense was USD 7.0 million versus USD 0.4 million because all previously unrecognized deferred tax Assets were recognized in the fourth quarter of 2025 and are no longer available to offset current expense.

Nine-month revenue was USD 244.6 million versus USD 205.9 million, and net product sales were USD 232.4 million versus USD 197.2 million. Income from operations was USD 123.1 million versus USD 71.7 million, and net income was USD 103.5 million, or USD 0.76 per diluted share, versus USD 76.4 million, or USD 0.55. Nine-month SG&A was USD 70.2 million and research and development was USD 37.1 million, while nine-month cost of revenue was USD 21.4 million versus USD 23.9 million and other income was USD 7.2 million versus other expense of USD 14.6 million. Total operating expenses for the third quarter were USD 48.3 million versus USD 43.7 million.

Pipeline and Capital

The company markets LUPKYNIS, the first FDA-approved oral therapy for adults with active lupus nephritis, and is developing aritinercept, a dual inhibitor of BAFF and APRIL for autoimmune diseases. It recently initiated PRESERVE, a Phase 4 multicenter study of LUPKYNIS in combination with belimumab, obinutuzumab or anifrolumab in lupus nephritis.

The board approved a share repurchase program of up to USD 150 million in February 2024 and added USD 150 million in July 2025, and the company has a Rule 10b5-1 plan to carry out repurchases. Cash, cash equivalents, restricted cash and investments were USD 486.9 million at September 30 versus USD 398.0 million at year end. Nine-month financing outflows were USD 53.2 million, mainly the repurchase of 5.0 million shares for USD 74.9 million, partly offset by USD 35.9 million of proceeds from Equity awards.

Demand and Spending Indicators

Items to watch include LUPKYNIS demand, the pace of aritinercept development spending, the tax rate and repurchase activity.